896466-04-9 | AT9283

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	in stock	$115.00	$81.00
10mg	98%	in stock	$206.00	$144.00
25mg	98%	in stock	$372.00	$261.00
50mg	98%	in stock	$573.00	$401.00

Description

• Catalog Number: AB47877
• Chemical Name: AT9283
• CAS Number: 896466-04-9
• Molecular Formula: C19H23N7O2
• Molecular Weight: 381.4316
• MDL Number: MFCD12031513
• SMILES: O=C(Nc1c[nH]nc1c1nc2c([nH]1)ccc(c2)CN1CCOCC1)NC1CC1

Computed Properties

• Complexity: 554
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 5
• XLogP3: 0.5

Literature

• AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.

  International journal of cancer 20120615

• A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120501

• Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro.

  Blood cells, molecules & diseases 20120315

• Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.

  Leukemia research 20110901

• Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110515

• AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer.

  Current opinion in investigational drugs (London, England : 2000) 20101201

• Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.

  Blood 20100923

• AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.

  British journal of haematology 20100701

• Aurora kinase inhibitors as anti-cancer therapy.

  Anti-cancer drugs 20100401

• Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.

  Cell cycle (Georgetown, Tex.) 20090615

• Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.

  Journal of medicinal chemistry 20090122